Novo Nordisk A-S

Novo Nordisk A-S

Yahoo Finance • 17 hours ago

Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Novo Nordisk presented long-term phase 3 data for denecimig (Mim8) prophylaxis in hemophilia pat... Full story

Yahoo Finance • 21 hours ago

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) today participate in one of the most exciting growth markets in healthcare: the weight loss drug market, one that's on track to reach nearly $100 billion in a few years. Novo was the first... Full story

Yahoo Finance • yesterday

Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximat... Full story

Yahoo Finance • 2 days ago

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S Bagsværd, Denmark, 13 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and... Full story

Yahoo Finance • 4 days ago

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

The S&P 500 index (SNPINDEX: ^GSPC) has a tiny little 1% yield today. Novo Nordisk (NYSE: NVO) is offering a 3.5% yield. Realty Income's (NYSE: O) yield is 5%. And Enterprise Products Partners' (NYSE: EPD) yield is an even higher 5.9%. Her... Full story

Yahoo Finance • 4 days ago

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?

Key Points Pfizer has regrouped in the GLP-1 space and is now working on a long-acting drug option. The company's update on the drug's development progress suggests it can compete with GLP-1 drugs from Eli Lilly and Novo Nordisk. 10 stock... Full story

Yahoo Finance • 5 days ago

AI Revolutionizes Cardiovascular Drug Development with $1.4+ Billion in Strategic Investments

BCC Research LLC "BCC Research examines how AI is transforming every stage of cardiovascular drug development—from target discovery and clinical trials to regulatory approval and post-market patient management—improving efficiency, safety... Full story

Yahoo Finance • 5 days ago

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week

Key Points Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.10 stocks we like better than Agios Pharmaceuticals... Full story

Yahoo Finance • 6 days ago

Novo Nordisk (NVO) In Focus After Wegovy Label Update As Undervalued Narrative Holds

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk (NYSE:NVO) is back in focus after Singapore regulators updated the label for Wegovy's semaglutide with da... Full story

Yahoo Finance • 6 days ago

Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With STEP UP Data

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk (NYSE:NVO) has updated the Wegovy label in Singapore to include new STEP UP trial data for adults with ob... Full story

Yahoo Finance • 6 days ago

Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Vivani Medical's new agreement gives Novo Nordisk (CPSE:NOVO B) ac... Full story

Yahoo Finance • 6 days ago

Fundsmith adds AppLovin, TSMC, Uber; exits Nike, LVMH, Novo Nordisk among 1H moves

Fundsmith Equity Fund was down by 2.9% in the first 6 months of the year, 14.1 percentage points less than what is perhaps the most obvious comparator, the MSCI World Index. The fund, in its semi-annual fund letter, stated that it began a... Full story

Yahoo Finance • 6 days ago

3 High Growth GLP-1 Biotech Winners to Buy in July

Quick Read LLY beat Q1 EPS estimates by 26% and launched Foundayo, while beaten-down NVO trades near 10x earnings and 45% below its 52-week high. Viking's pre-revenue VKTX carries binary Phase 3 risk, but VK2735 showed 12% mean body weigh... Full story

Yahoo Finance • 7 days ago

Leading bank backs European pharma as the cleaner alternative to the AI trade

Leading bank backs European pharma as the cleaner alternative to the AI trade Proactive uses images sourced from Shutterstock UBS has reiterated its overweight stance on European pharmaceuticals, framing the sector as a more resilient hom... Full story

Yahoo Finance • 8 days ago

Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Viv... Full story

Yahoo Finance • 8 days ago

Eli Lilly's Market Cap Balloons Again On This IPO's Setback

Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill. Continue Reading... Full story

Yahoo Finance • 8 days ago

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

Key Points CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pip... Full story

Yahoo Finance • 8 days ago

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical, Inc. Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Compan... Full story

Yahoo Finance • 9 days ago

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Key Points Eli Lilly and dominance in weight loss and diabetes treatments continues to fuel massive revenue growth. Teva Pharmaceutical Industries offers a value-oriented play as it moves past legal hurdles and expands its biosimilar port... Full story

Yahoo Finance • 9 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

European equities traded in the US as American depositary receipts were tracking modestly higher lat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story